z-logo
open-access-imgOpen Access
A MultiCenter Pilot Randomized Controlled Trial of Remote Ischemic Preconditioning in Major Vascular Surgery
Author(s) -
Donagh Healy,
E. Boyle,
Damian McCartan,
Michael Bourke,
Mekki Medani,
John Ferguson,
Hatim Yagoub,
Khalid Bashar,
M O'Donnell,
John Newell,
Catriona Canning,
Morgan McMonagle,
Joseph Dowdall,
Simon S. Cross,
S. O'Daly,
Brian J. Manning,
Gregory J. Fulton,
Eamon G. Kavanagh,
P. Burke,
Pierce A. Grace,
Mary Moloney,
Stewart R. Walsh
Publication year - 2015
Publication title -
vascular and endovascular surgery/vascular and endovascular surgery
Language(s) - English
Resource type - Journals
eISSN - 1938-9116
pISSN - 1538-5744
DOI - 10.1177/1538574415614404
Subject(s) - medicine , revascularization , myocardial infarction , randomized controlled trial , abdominal aortic aneurysm , vascular surgery , cardiology , carotid endarterectomy , clinical endpoint , ischemic preconditioning , clinical trial , surgery , cardiac surgery , ischemia , aneurysm , stenosis
A pilot randomized controlled trial that evaluated the effect of remote ischemic preconditioning (RIPC) on clinical outcomes following major vascular surgery was performed. Eligible patients were those scheduled to undergo open abdominal aortic aneurysm repair, endovascular aortic aneurysm repair, carotid endarterectomy, and lower limb revascularization procedures. Patients were randomized to RIPC or to control groups. The primary outcome was a composite clinical end point comprising any of cardiovascular death, myocardial infarction, new-onset arrhythmia, cardiac arrest, congestive cardiac failure, cerebrovascular accident, renal failure requiring renal replacement therapy, mesenteric ischemia, and urgent cardiac revascularization. Secondary outcomes were components of the primary outcome and myocardial injury as assessed by serum troponin values. The primary outcome occurred in 19 (19.2%) of 99 controls and 14 (14.1%) of 99 RIPC group patients ( P = .446). There were no significant differences in secondary outcomes. Our trial generated data that will guide future trials. Further trials are urgently needed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom